NCT05861947 2026-04-17
JIVAN
Aurigene Discovery Technologies Limited
Phase 1 Terminated
Clinical Trials
28 trialsNCT05865002 2026-04-17
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
Phase 1 Recruiting
NCT06760702 2026-04-17
TEJAS-2
Aurigene Discovery Technologies Limited
Phase 2 Terminated
NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06525831 2026-04-14
Rein3DP-M
University Hospital, Bordeaux
Phase NA Recruiting
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT00579514 2026-04-07
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05665361 2026-04-07
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT07195682 2026-04-07
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07227415 2026-04-07
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07401875 2026-04-02
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06948552 2026-04-01
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Henry Ford Health System
Phase 2 Recruiting
NCT07011719 2026-04-01
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03786796 2026-03-30
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05536141 2026-03-30
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05700461 2026-03-20
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Phase 1 Enrolling by invitation
NCT06126159 2026-03-20
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
Chang Gung Memorial Hospital
Phase NA Active not recruiting
NCT06882486 2026-03-20
NAMECAR
Institut Paoli-Calmettes
Phase NA Recruiting
NCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT03185039 2026-03-19
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Institut Paoli-Calmettes
Phase NA Active not recruiting